Convergence Pharmaceuticals

Convergence Pharmaceuticals is a biotechnology company focused on the development of novel analgesics for the treatment of chronic pain.

Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (“GSK”). Convergence Pharmaceuticals has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signaling through modulation of specific ion-channels.